Drug Trial Radar · NCT07613710
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Jun 13, 2025
Primary completion
Feb 9, 2027
Study completion Feb 16, 2027
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.
Conditions
- Narcolepsy
Interventions
Lu AH69593Drug
Lu AH69593 will be administered per schedule specified in the arm description.
PlaceboDrug
Placebo will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 90
- Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)Time frame: Baseline up to Day 84
- Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to StimuliTime frame: Baseline, up to Day 11
- PVT Parameter - Change From Baseline in Number of Errors of OmissionTime frame: Baseline, up to Day 11
- PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)Time frame: Baseline, up to Day 11
- Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline up to Day 90
- Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593Time frame: Up to 84 days
- Maximum Observed Plasma Concentration (Cmax) of Lu AH69593Time frame: Up to 84 days
- Time to Reach Cmax (Tmax) of Lu AH69593Time frame: Up to 84 days
- AUC From Time Zero to Infinity (AUC0-inf)Time frame: Up to 6 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Terveystalo Helsinki, Sleep Clinic
Helsinki, Finland · Recruiting
CRST, Clinical Research Services Turku
Turku, Finland · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.